Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Not giving up on Afrezza, MannKind anticipates US FDA meeting to firm up trials

This article was originally published in Scrip

Executive Summary

MannKind investors are holding their breathes that all goes well during a 10 August meeting with the US FDA, in which the firm will finalize plans for two new pivotal trials of its long-embattled inhaled insulin drug Afrezza (insulin human rDNA origin), which was rejected by the agency in January (scripintelligence, 20 January 2011).

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC013990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel